NasdaqGM - Nasdaq Real Time Price USD

Protara Therapeutics, Inc. (TARA)

3.9400

+0.0900

+(2.34%)

At close: April 22 at 4:00:00 PM EDT

4.0975

+0.16

+(4.00%)

Pre-Market: 8:47:47 AM EDT

Protara Therapeutics to Host Conference Call and Webcast to Review Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC on Monday, April 28, 2025

NEW YORK, April 23, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Monday, April 28, 2025, to review updated safety and efficacy data from the ongoing Phase 2 open-label ADVANCED-2 trial of TARA-002 in patients with non-muscle invasive bladder cancer (NMIBC), including data from patients

GlobeNewswire 47 minutes ago

TARA
+2.34%
Protara Therapeutics Announces Appointment of Leonardo Viana Nicacio, M.D., as Chief Medical Officer

NEW YORK, April 15, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the appointment of Leonardo Viana Nicacio, M.D., as Chief Medical Officer. Dr. Nicacio brings to Protara nearly 20 years of broad oncology, drug development, regulatory and commercial experience across leading biopharmaceutical and health technology companies. “We are delighted to welcom

GlobeNewswire 7 days ago

TARA
+2.34%
Protara Therapeutics to Present Interim Analysis from the Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the American Urological Association Annual Meeting

NEW YORK, April 10, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that two presentations and a panel discussion highlighting the ongoing Phase 2 open-label ADVANCED-2 trial of TARA-002 in patients with non-muscle invasive bladder cancer (NMIBC) will be featured at the upcoming American Urological Association (AUA) 2025 Annual Meeting taking place from

GlobeNewswire 12 days ago

TARA
+2.34%
Protara Therapeutics Announces Encore Presentation of Results from THRIVE-1 Prospective Observational Study Evaluating the Prevalence of Choline Deficiency and Liver Injury in Patients Dependent on Parenteral Support

Data to be featured during oral presentation at the American Society for Parenteral and Enteral Nutrition 2025 Nutrition Science & Practice ConferenceDosing of first patient in THRIVE-3 registrational trial of IV Choline Chloride in patients dependent on parenteral support expected in 1H 2025 NEW YORK, March 19, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today anno

GlobeNewswire last month

TARA
+2.34%
Protara Therapeutics (NASDAQ:TARA) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Simply Wall St. last month

TARA
+2.34%
Protara Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

Reported positive six-month data from ADVANCED-2 trial of TARA-002 in patients with NMIBC; Announcement of initial data from 12-month evaluable patients expected by mid-2025Dosing of first patient in THRIVE-3 registrational trial of IV Choline Chloride in patients dependent on parenteral support expected in 1H 2025On track to provide an interim update from the Phase 2 STARBORN-1 trial of TARA-002 in pediatric LMs patients by the end of 1H 2025Cash, cash equivalents and investments of $170 millio

GlobeNewswire last month

TARA
+2.34%
Protara Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Wednesday, March 5, 2025, at 9:50 am ET in Boston. A live webcast of the fireside chat can be accessed by visiting the Events and Presentations section of the Company’s website: https

GlobeNewswire last month

TARA
+2.34%
Protara Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in a virtual fireside chat at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on Wednesday, February 12, 2025, at 12:40 pm ET. A live webcast of the fireside chat can be accessed by visiting the Events and Presentations section of the Compa

GlobeNewswire 2 months ago

TARA
+2.34%
Protara Highlights Recent Updates and Anticipated 2025 Milestones

Reported positive six-month data from ADVANCED-2 trial of TARA-002 in patients with NMIBC Completed approximately $100 million public offering, extending runway into 2027 Initial data from 12-month evaluable NMIBC patients in ADVANCED-2 trial expected in mid-2025; Results from a futility analysis of approximately 25 six-month evaluable BCG-Unresponsive patients expected by the end of 2025 Dosing of first patient in THRIVE-3 registrational trial of IV Choline Chloride in patients dependent on par

GlobeNewswire 3 months ago

TARA
+2.34%
Protara Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

NEW YORK, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will present at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2025, at 7:30 am PT in San Francisco. A live webcast of the presentation can be accessed by visiting the Events and Presentations section of the Company’s website: https://ir.protara

GlobeNewswire 3 months ago

TARA
+2.34%
Protara Announces Closing of $100 Million Public Offering

NEW YORK, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the closing of its underwritten public offering of 13,690,000 shares of its common stock at a public offering price of $6.25 per share and pre-funded warrants to purchase 2,325,372 shares of common stock at a price of $6.249 per pre-funded warrant, which represents the per share price for

GlobeNewswire 4 months ago

TARA
+2.34%
Protara Announces Pricing of $100 Million Public Offering

NEW YORK, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA) (“Protara”), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the pricing of its underwritten public offering of 13,690,000 shares of its common stock at a price to the public of $6.25 per share and pre-funded warrants to purchase 2,325,372 shares of common stock at a price of $6.249 per pre-funded warrant, which represents the per share

GlobeNewswire 4 months ago

TARA
+2.34%
Protara Announces Proposed Public Offering

NEW YORK, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA) (“Protara”), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that it has commenced an underwritten public offering of shares of its common stock or, in lieu of issuing common stock to certain investors, pre-funded warrants to purchase shares of its common stock. All of the shares of common stock and pre-funded warrants to be sold in the

GlobeNewswire 4 months ago

TARA
+2.34%
Institutions profited after Protara Therapeutics, Inc.'s (NASDAQ:TARA) market cap rose US$60m last week but individual investors profited the most

Key Insights Significant control over Protara Therapeutics by individual investors implies that the general public has...

Simply Wall St. 4 months ago

TARA
+2.34%
Protara Announces Positive Results from the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC

TARA-002 demonstrates 72% six-month landmark complete response rate and 70% complete response rate at any time across BCG exposures100% six-month landmark complete response rate and 80% complete response rate at any time observed in BCG-Unresponsive patients64% six-month landmark complete response rate and 67% complete response rate at any time observed in BCG-Naïve patients80% reinduction salvage rate and compelling durability observed with 100% of patients maintaining a complete response from

GlobeNewswire 4 months ago

TARA
+2.34%
Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC on Thursday, December 5, 2024

NEW YORK, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, December 5, 2024, to review new data from an interim analysis of the ongoing Phase 2 open-label ADVANCED-2 trial of TARA-002 in patients with non-muscle invasive bladder cancer (NMIBC). The data will be featured

GlobeNewswire 4 months ago

TARA
+2.34%
Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the 25th Annual Meeting of the Society of Urologic Oncology

NEW YORK, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that data from an interim analysis of the ongoing Phase 2 open-label ADVANCED-2 trial of TARA-002 in patients with non-muscle invasive bladder cancer (NMIBC) will be featured during a poster session at the upcoming 25th Annual Meeting of the Society of Urologic Oncology (SUO) taking place

GlobeNewswire 5 months ago

TARA
+2.34%
Protara Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update

On track to report interim data in six-month evaluable patients in ADVANCED-2 trial of TARA-002 in NMIBC in 4Q 2024Expect to report interim 12-month data in ADVANCED-2 trial of TARA-002 in NMIBC in mid-2025In pediatric LMs patients, TARA-002 demonstrated encouraging results and was generally well-tolerated in the first cohort of Phase 2 STARBORN-1 trial; initial results from next cohort expected in 1H 2025Received Fast Track designation from the U.S. FDA for IV Choline Chloride; expect to dose f

GlobeNewswire 5 months ago

TARA
+2.34%
Protara Therapeutics to Present at the Guggenheim Inaugural Healthcare Innovation Conference

NEW YORK, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in a fireside chat at the Guggenheim Inaugural Healthcare Innovation Conference on Wednesday, November 13, 2024, at 2:00 pm ET in Boston. A live webcast of the fireside chat can be accessed by visiting the Events and Presentations section of the Company’s

GlobeNewswire 5 months ago

TARA
+2.34%
Protara Therapeutics Granted FDA Fast Track Designation for Intravenous Choline Chloride for Patients Receiving Parenteral Support

Remain on track to initiate registrational THRIVE-3 trial in 1Q’ 2025 NEW YORK, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Intravenous (IV) Choline Chloride, the Company’s investigational IV phospholipid substrate replacement therapy, as a source of choli

GlobeNewswire 5 months ago

TARA
+2.34%

Performance Overview

Return	TARA	S&P 500 (^GSPC)
YTD	-25.38%	-10.10%
1-Year	+29.18%	+5.53%
3-Year	-10.86%	+23.78%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Protara Therapeutics, Inc. (TARA)

Protara Therapeutics to Host Conference Call and Webcast to Review Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC on Monday, April 28, 2025

Protara Therapeutics Announces Appointment of Leonardo Viana Nicacio, M.D., as Chief Medical Officer

Protara Therapeutics to Present Interim Analysis from the Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the American Urological Association Annual Meeting

Protara Therapeutics Announces Encore Presentation of Results from THRIVE-1 Prospective Observational Study Evaluating the Prevalence of Choline Deficiency and Liver Injury in Patients Dependent on Parenteral Support

Protara Therapeutics (NASDAQ:TARA) Is In A Good Position To Deliver On Growth Plans

Protara Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

Protara Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

Protara Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Protara Highlights Recent Updates and Anticipated 2025 Milestones

Protara Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Protara Announces Closing of $100 Million Public Offering

Protara Announces Pricing of $100 Million Public Offering

Protara Announces Proposed Public Offering

Institutions profited after Protara Therapeutics, Inc.'s (NASDAQ:TARA) market cap rose US$60m last week but individual investors profited the most

Protara Announces Positive Results from the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC

Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC on Thursday, December 5, 2024

Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the 25th Annual Meeting of the Society of Urologic Oncology

Protara Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update

Protara Therapeutics to Present at the Guggenheim Inaugural Healthcare Innovation Conference

Protara Therapeutics Granted FDA Fast Track Designation for Intravenous Choline Chloride for Patients Receiving Parenteral Support

Performance Overview